Discover nano2026ReviewNon-viral Gene DeliveryDrug Delivery
Aadil Kr, Bhange K, Kommineni N, Mishra G, Bunekar N, Jha A, Et Al.
Messenger RNA (mRNA)-based therapeutics have transformed cancer treatment strategies, especially after the success of lipid nanoparticle (LNP)-enabled mRNA vaccines. LNPs are effective non-viral delivery vehicles that protect mRNA, enhance intracellular delivery, and improve therapeutic safety. This review discusses…
Read the article →Advances in pharmacological and pharmaceutical sciences2026ReviewNon-viral Gene DeliveryDrug Delivery
Abudayah Aa
Mucin, a highly glycosylated macromolecular component of mucus, has traditionally been regarded as a biological barrier that restricts drug transport across mucosal surfaces. Growing evidence, however, has repositioned mucin as a functional and engineerable biomaterial with distinctive potential for advanced drug…
Read the article →Advanced pharmaceutical bulletin2026ReviewDrug Delivery
Hari M, Subramony A, Dwivedi D, Krishnan Rs, Damodaran A, Nair Sc
Treatment for Parkinson's disease (PD) faces two significant challenges: first, the blood-brain barrier (BBB) and second, a therapeutic strategy that alleviates symptoms instead of stopping the disease progression. The BBB prevents over 98% of small-molecule drugs, leaving neuroprotective options mostly inaccessible…
Read the article →Advanced pharmaceutical bulletin2026ReviewDrug Delivery
Ainurofiq A, Rosalin Ea, Istiyono Ms, Maharani Na, Fauzy R, Sugiharti Sn, Et Al.
Chronic Obstructive Pulmonary Disease (COPD) is a condition that poses major challenges in therapeutic management, primarily due to the limitations of conventional inhalation methods in achieving optimal drug deposition and maintaining therapeutic effects over a long period. Inhalable nanomedicine has emerged as an…
Read the article →Biomacromolecules2026ResearchDrug Delivery
Hall Cb, Tan L, Okai Dna, Dobler S, Adigun R, Okuwobi Cb, Et Al.
Herein, we characterize a class of PAMAM/acyl synthetic lipids and their self-assembled nanostructures. We explicitly determined the impact of hydrocarbon length, saturation, and synthetic lipid volume on the properties of the self-assembled, single-component nanostructure. The synthesis of the PAMAM-acyl lipid…
Read the article →Current opinion in neurology2026ReviewDrug Delivery
Nakhate V, Wen Py
Drug delivery across the blood-brain barrier (BBB) remains an important challenge in the treatment of brain tumors. This review summarizes the physiologic barriers to effective CNS drug exposure and evaluates strategies to improve delivery, with a focus on glioma. Recent advances span three complementary approaches…
Read the article →Frontiers in immunology2026ReviewDrug Delivery
Di Domenico O, Marrapodi Mm, Di Feo G, Argenziano L, Rossi F, Di Paola A
Pediatric immune thrombocytopenia (ITP) is an acquired immune-mediated disorder triggered by autoantibody production directed against glycoproteins on the platelet surface, leading to platelet destruction in the spleen and impaired megakaryopoiesis in the bone marrow. The immune response is further compromised by a…
Read the article →Cardiovascular therapeutics2026ReviewDrug Delivery
Sivanathan B, Bobbala S, Venkatesh S
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, yet most therapies lack cardiovascular tissue- and cell-specificity, limiting efficacy and increasing off-target toxicity. Nanoparticle-based drug delivery systems offer opportunities to enhance myocardial targeting, improve…
Read the article →Molecular medicine reports2026ReviewDrug Delivery
Liu H, Yan H, Liu S, Xue Y, Huang J, Li S
Graphene‑based nanomaterials have emerged as a versatile platform for tumour‑targeted drug delivery owing to their unique physicochemical properties, including large specific surface area, structural flexibility and tuneable surface chemistry. Graphene oxide (GO) and reduced GO have been extensively investigated as…
Read the article →Exploration (Beijing, China)2026ReviewDrug Delivery
Lin Yj, Komperda I
Although nanomedicines offer advanced formulation control and physicochemical characterization, clinical translation has been limited. Delivery meta-analyses and late-stage attrition indicate biological validation is often a bottleneck. It must account for context-dependent processes such as protein corona formation…
Read the article →Nanomedicine (London, England)2026ResearchDrug Delivery
Tunc Cu, Saha Sk, Panda Ss, Mori S, Culha M
DNA nanotechnology has emerged as a highly programmable platform in nanomedicine, enabling the fabrication of precise nanoscale architectures for drug delivery, biosensing, gene regulation, immunotherapy, and theranostics. DNA-based nanocarriers offer distinctive advantages, including structural programmability…
Read the article →Discover nano2026ReviewDrug Delivery
Guan X, Hou X, Meng W, Guo Hd
Extracellular vesicles have garnered significant attention in the biomedical field due to their potential as therapeutic agents and diagnostic tools. Bovine milk extracellular vesicles (BMEVs), in particular, have emerged as a promising tool in biomedical research due to their unique biocompatibility, stability, and…
Read the article →European journal of medicinal chemistry2026ReviewDrug Delivery
Alahmary La, Sukkarieh Fa, Ferdous Ut, Helal A, Uddin S
Metal-organic frameworks (MOFs) are tuneable porous platforms for cancer drug delivery, as their metal nodes, organic linkers, pore architecture, and surface chemistry can be engineered to control cargo loading, targeting, degradation, and stimulus-responsive release. This review critically discusses the…
Read the article →Molecules (Basel, Switzerland)2026ReviewDrug Delivery
Lee M, Choi Y, Yoon Sj, Kim M
Extracellular vesicles (EVs) have emerged as promising therapeutic carriers owing to their biocompatibility, low immunogenicity, and ability to transport diverse biological cargo. However, successful EV-based therapy depends not only on carrier engineering but also on selecting an administration route appropriate for…
Read the article →Pharmaceutics2026ReviewDrug Delivery
Ban M, Zhao S, Liu Z, Zhao L
Cancer remains a major global health challenge, and nanoparticle-based drug delivery systems have emerged as a promising strategy for targeted cancer therapy. However, clinical translation is still limited by an incomplete understanding of how nanoparticles navigate the tumor microenvironment (TME) throughout the…
Read the article →Acta pharmaceutica (Zagreb, Croatia)2026ResearchNon-viral Gene DeliveryDrug Delivery
Li N, Qu Z, Du D
The application of nanotechnology in drug delivery systems has attracted considerable scientific interest, particularly with respect to improving the therapeutic efficacy and safety profiles of pharmacological agents. This review critically examines nanotechnology-based drug delivery systems for the management of…
Read the article →International journal of nanomedicine2026ReviewNon-viral Gene DeliveryDrug Delivery
Thalij Km, You Hw, Habeeb M, Ratchagar Jv, Khot Vs, Gorde Pl
Hepatocellular carcinoma is the sixth most common cancer worldwide and a leading cause of cancer related mortality. Risk factors include chronic hepatitis B/C, obesity, alcohol abuse, diabetes and metabolic disorders. In advanced stages, normal treatments such as surgery, transplantation and chemotherapy are not as…
Read the article →Advanced materials (Deerfield Beach, Fla.)2026ResearchDrug Delivery
Knol Ra, Hu B, Bobylev Eo, Farber M, Laan Pcm, Kock Tjf, Et Al.
Inorganic anticancer drugs such as cisplatin remain central to chemotherapy but are limited by poor tumor selectivity, rapid clearance, and off-target toxicity. We recently developed cationic Pt 2 L 4 nanocages with 12-fold higher anticancer activity than cisplatin in PC-3M-Pro4 cells in vitro, but their positive…
Read the article →Journal of controlled release : official journal of the Controlled Release Society2026ResearchNon-viral Gene DeliveryDrug Delivery
Jacobs W, De Zwaan K, Rutten L, Van Wessel T, Boltje Tj, Cano Lq, Et Al.
Non-viral nanocarriers for oligonucleotide delivery have enormous therapeutic potential, but the factors determining cell type-specific uptake remain incompletely understood. One major cell surface component that delivery vectors encounter is the glycocalyx. While membrane glycans are established interactors for many…
Read the article →ACS applied bio materials2026ResearchDrug Delivery
Kumar A, Patri Sv, Chilumula S, Arjunan P, Ayyanar V, Hanchate P, Et Al.
The clinical effectiveness of doxorubicin (DOX) in hepatocellular carcinoma (HCC) remains constrained by poor tumor selectivity and the emergence of multidrug resistance. In this work, we examine how the electronic nature of the C-5 substituent on uracil-based nucleoside lipids shapes the physicochemical and…
Read the article →Small2025ReviewNon-viral Gene DeliveryDrug Delivery
S Sarmah, S Baidya, M De
This review surveys lipid nanoparticle composition, ionisable lipid synthesis and strategies to target delivery of fragile RNA therapeutics while addressing tissue selectivity and immune activation.
Read the article →Journal of Controlled Release 341 (2022ResearchNon-viral Gene Delivery
Kelsey L. Swingle, Margaret M. Billingsley, Sourav K. Bose, Brandon White, Rohan Palanki, Apeksha Dave, Savan K. Patel, Ningqiang Gong, Alex G. Hamilton, Mohamad-Gabriel Alameh, Drew Weissman, William H. Peranteau, Michael J. Mitchell
Congenital protein deficiencies often begin irreversible pathology in utero, but postnatal treatments are limited. In utero mRNA delivery could enable protein replacement before disease onset, yet LNP stability in fetal amniotic fluid and how it affects mRNA delivery had not been previously investigated. LNP A12 was…
Read the article →Advanced Science.2022ReviewDrug Delivery
De R, Mahata Mk, Kim K-T
Drug carriers are as important as drugs themselves, but clinical translation of polymeric nanocarriers (PNCs) remains limited by incomplete understanding of how carrier architecture and physicochemical properties affect loading, circulation, targeting, and release. The review addresses this gap by systematically…
Read the article →Stem Cell Research & Therapy2021ReviewNon-viral Gene Delivery
Farough Marofi, Roza Motavalli, Vladimir A. Safonov, Lakshmi Thangavelu, Alexei Valerievich Yumashev, Markov Alexander, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Mostafa Jarahian, Sepideh Izadi, Ali Hassanzadeh, Naghmeh Shirafkan, Safa Tahmasebi, Farhad Motavalli Khiavi
CAR T cell therapy has transformed treatment of hematologic malignancies, but its efficacy in solid tumours remains unsupported. Solid tumours present distinct barriers—antigen heterogeneity, poor T cell trafficking/infiltration, and an immunosuppressive tumour microenvironment (TME)—that limit CAR T cell function…
Read the article →